Predictors of reoperation after lung volume reduction surgery

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 1,37 MB, PDF-dokument

Objectives
Lung volume reduction surgery (LVRS) has proven an effective treatment for emphysema, by decreasing hyperinflation and improving lung function, activity level and reducing dyspnoea. However, postoperative air leak is an important complication, often leading to reoperation.

Our aim was to analyse reoperations after LVRS and identify potential predictors.

Methods
Consecutive single-centre unilateral VATS LVRS performed from 2017 to 2022 were included. Typically, 3–5 minor resections were made using vascular magazines without buttressing. Data were obtained from an institutional database and analysed. Multivariable logistic regression was used to identify predictors of reoperation. Number and location of injuries were registered.

Results
In total, 191 patients were included, 25 were reoperated (13%). In 21 patients, the indication for reoperation was substantial air leak, 3 patients bleeding and 1 patient empyema. Length of stay (LOS) was 21 (11–33) vs. 5 days (3–11), respectively. Only 3 injuries were in the stapler line, 13 within < 2cm and 15 injuries were in another site. Multivariable logistic regression analysis showed that decreasing DLCO increased risk of reoperation, OR 1.1 (1.03, 1.18, P = 0.005). Resections in only one lobe, compared to resections in multiple lobes, were also a risk factor OR 3.10 (1.17, 9.32, P = 0.03). Patients undergoing reoperation had significantly increased 30-day mortality, OR 5.52 (1.03, 26.69, P = 0.02).

Conclusions
Our incidence of reoperation after LVRS was 13% leading to prolonged LOS and increased 30-day mortality. Low DLCO and resections in a single lobe were significant predictors of reoperation. The air leak was usually not localized in the stapler line.
OriginalsprogEngelsk
TidsskriftSurgical Endoscopy
Vol/bind38
Udgave nummer2
Sider (fra-til)679-687
Antal sider9
ISSN0930-2794
DOI
StatusUdgivet - 2024

Bibliografisk note

Funding Information:
Open access funding provided by Royal Library, Copenhagen University Library. This study was supported with a research grant from Medtronic.

Funding Information:
Alberte Lund: Research grant received from Medtronic, Patrick Soldath: None, Erika Helena Nodin: None, Henrik Jessen Hansen: Speaker fee from BD and Medtronic. Kristine Jensen: Speakers honorary from PulmonX, Anna Kalhauge: None, Kåre Hornbech: None, Michael Perch: received speakers honorary from Astra-Zeneca, Chiesi, Novartis, PulmonX, Takeda and Therakos. Institutional research grant from Roche and PulmonX. Boeringer-Ingelheim supported congress participation. Jann Mortensen: None, René Horsleben Petersen: Research grant received from Medtronic. Speaker fee from Medtronic, AMBU, AstraZeneca, Medela. Advisory board for AstraZeneca, MSD, Roche, Bristol Myers Squibb.

Publisher Copyright:
© 2023, The Author(s).

ID: 382982465